Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,236.00    -2.00 (-0.16%)
Bid:
1,239.00
Ask:
1,240.00
Spread: 1.00 (0.081%)
Market Cap: £854.29m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Response to CMA Summary Final Decision Report

24 Mar 2026 07:13

RNS Number : 8560X
CVS Group plc
24 March 2026
 

For Immediate Release 24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its Final Decision Report in the veterinary services market investigation. The CMA is expected to publish its full Final Decision Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above those announced in its provisional decision. We are pleased to see that the CMA has considered our and the veterinary profession's feedback in amending the proposed fee cap on prescriptions with the cap now increased to £21 inclusive of VAT for the first drug prescribed, with the ability to charge an additional £12.50 for each additional drug prescribed at the same time. Whilst we continue to believe that some of these remedies are not fully justified, we are comfortable with them and believe they are workable. We already comply with many remedies and are well advanced in complying with others, with price lists published on our practice websites in late 2025 and 117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market expectations.

 

Whilst the remedies are now certain and will not change, we look forward to discussing the practical implementation of all remedies with the CMA prior to the publication of its Final Order later in 2026 which will bring these remedies into legal effect.

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPPPURUWUPQUMC
Date   Source Headline
29th Nov 20187:00 amRNSAnnual General Meeting Trading Update
14th Nov 201811:48 amRNSHolding(s) in Company
12th Nov 20183:56 pmRNSHolding(s) in Company
12th Nov 20183:50 pmRNSHolding(s) in Company
6th Nov 20185:11 pmRNSPosting of Annual Report and Notice of AGM
5th Nov 20188:05 amRNSExercise of Options, Directors' Dealing and TVR
31st Oct 20185:32 pmRNSTotal Voting Rights
24th Oct 201810:43 amRNSHolding(s) in Company
16th Oct 201812:51 pmRNSLong Term Incentive Plan Awards
15th Oct 20187:00 amRNSHolding(s) in Company
4th Oct 20187:00 amRNSExercise of Options and Total Voting Rights
27th Sep 20187:00 amRNSPreliminary Results
21st Sep 20184:21 pmRNSHolding(s) in Company
21st Sep 20184:21 pmRNSHolding(s) in Company
24th Aug 201812:22 pmRNSHolding(s) in Company
23rd Aug 20182:56 pmRNSHolding(s) in Company
21st Aug 20184:22 pmRNSHolding(s) in Company
21st Aug 20183:32 pmRNSHolding(s) in Company
2nd Aug 20187:00 amRNSTrading Statement & Board Update
31st Jul 20185:45 pmRNSExercise of Options and Total Voting Rights
20th Jul 20187:00 amRNSBoard Changes and Notice of Trading Update
10th Jul 201810:35 amRNSHolding(s) in Company
6th Jul 20185:11 pmRNSHolding(s) in Company
2nd Jul 20184:51 pmRNSDirector/PDMR Shareholding
2nd Jul 20184:46 pmRNSTotal Voting Rights
2nd Jul 20183:05 pmRNSHolding(s) in Company
19th Jun 20187:00 amRNSBlock listing Interim Review
7th Jun 20184:18 pmRNSHolding(s) in Company
31st May 20183:40 pmRNSExercise of Options and Total Voting Rights
22nd May 20182:47 pmRNSHolding(s) in Company
18th May 20184:33 pmRNSHolding(s) in Company
10th May 20182:33 pmRNSHolding(s) in Company
4th May 20185:31 pmRNSHolding(s) in Company
30th Apr 20184:47 pmRNSTotal Voting Rights
24th Apr 20183:13 pmRNSHolding(s) in Company
23rd Apr 20185:55 pmRNSHolding(s) in Company
10th Apr 20182:26 pmRNSExercise of Options & TVR
4th Apr 201812:05 pmRNSDirector/PDMR and PCA Shareholding
3rd Apr 20188:20 amRNSHolding(s) in Company
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20184:42 pmRNSExercise of Options, Director/PCA Dealing & TVR
20th Mar 20183:06 pmRNSExercise of Options, Directors' dealings and TVR
1st Mar 20183:30 pmRNSTotal Voting Rights
21st Feb 20184:17 pmRNSHolding(s) in Company
16th Feb 20185:36 pmRNSResult of Placing
16th Feb 201812:45 pmRNSPlacing Update
16th Feb 201811:05 amRNSClose of Accelerated Bookbuild
16th Feb 20187:01 amRNSProposed Accelerated Bookbuild
16th Feb 20187:00 amRNSInterim Results
15th Feb 20187:00 amRNSExercise of Options & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.